|
CA2890935A1
(en)
|
2012-11-08 |
2014-05-15 |
Bristol-Myers Squibb Company |
Alkyl amide-substituted pyrimidine compounds useful in the modulation of il-12, il-23 and/or ifn.alpha.
|
|
PT2922846T
(pt)
|
2012-11-08 |
2018-12-19 |
Bristol Myers Squibb Co |
Compostos heterocíclicos substituídos por amida úteis como moduladores de il-12, il-23 e/ou ie'n-alfa
|
|
CA2890983A1
(en)
|
2012-11-08 |
2014-05-15 |
Bristol-Myers Squibb Company |
Heteroaryl substituted pyridyl compounds useful as kinase modulators
|
|
AR094537A1
(es)
|
2013-11-07 |
2015-08-12 |
Bristol Myers Squibb Co |
COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
|
|
ES2702126T3
(es)
|
2013-12-10 |
2019-02-27 |
Bristol Myers Squibb Co |
Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
|
|
TW201609693A
(zh)
|
2014-01-03 |
2016-03-16 |
必治妥美雅史谷比公司 |
雜芳基取代之菸鹼醯胺化合物
|
|
WO2016001341A1
(en)
*
|
2014-07-03 |
2016-01-07 |
F. Hoffmann-La Roche Ag |
Sulfonylaminopyridine compounds, compositions and methods of use
|
|
WO2016022626A1
(en)
*
|
2014-08-06 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
Heterocyclic cgrp receptor antagonists
|
|
CN107849039B
(zh)
|
2015-06-24 |
2020-07-03 |
百时美施贵宝公司 |
经杂芳基取代的氨基吡啶化合物
|
|
TW201713663A
(zh)
|
2015-06-24 |
2017-04-16 |
必治妥美雅史谷比公司 |
經雜芳基取代之胺基吡啶化合物
|
|
KR102641263B1
(ko)
|
2015-06-24 |
2024-02-26 |
브리스톨-마이어스 스큅 컴퍼니 |
헤테로아릴 치환된 아미노피리딘 화합물
|
|
MX379776B
(es)
*
|
2015-11-26 |
2025-03-11 |
Novartis Ag |
Derivados de diamino piridina para usarse en el tratamiento de dermatitis atópica o psoriasis.
|
|
JP7082130B2
(ja)
|
2016-10-14 |
2022-06-07 |
ニンバス ラクシュミ， インコーポレイテッド |
Ｔｙｋ２阻害剤およびその使用
|
|
AU2017345736B2
(en)
|
2016-10-21 |
2022-04-07 |
Takeda Pharmaceutical Company Limited |
TYK2 inhibitors and uses thereof
|
|
AR110351A1
(es)
*
|
2016-12-13 |
2019-03-20 |
Bristol Myers Squibb Co |
COMPUESTOS DE HETEROARILO SUSTITUIDOS CON FOSFINÓXIDO ALQUILAMIDA COMO MODULADORES DE RESPUESTAS DE IL-12, IL-23 Y/O IFNa
|
|
EP4338802A3
(en)
|
2017-03-08 |
2024-09-04 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors, uses, and methods for production thereof
|
|
US10829496B2
(en)
|
2017-05-11 |
2020-11-10 |
Bristol-Myers Squibb Company |
Thienopyridines and benzothiophenes useful as IRAK4 inhibitors
|
|
TWI776810B
(zh)
*
|
2017-05-12 |
2022-09-11 |
瑞士商諾華公司 |
新穎二胺基吡啶衍生物
|
|
CN111194317A
(zh)
|
2017-07-28 |
2020-05-22 |
林伯士拉克许米公司 |
Tyk2抑制剂与其用途
|
|
EP3713930A1
(en)
*
|
2017-11-21 |
2020-09-30 |
Bristol-Myers Squibb Company |
Sulfone pyridine alkyl amide-substituted heteroaryl compounds
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
WO2019160875A1
(en)
|
2018-02-13 |
2019-08-22 |
Rutgers, The State University Of New Jersey |
Antibacterial agents: soluble salts and aqueous formulations of pyronins
|
|
WO2019160873A1
(en)
|
2018-02-13 |
2019-08-22 |
Rutgers, The State University Of New Jersey |
Antibacterial agents: o-alkyl-deuterated pyronins
|
|
US11572337B2
(en)
|
2018-03-06 |
2023-02-07 |
Rutgers, The State University Of New Jersey |
Antibacterial agents: arylalkylcarboxamido phloroglucinols
|
|
JP6557436B1
(ja)
|
2018-03-12 |
2019-08-07 |
アッヴィ・インコーポレイテッド |
チロシンキナーゼ２媒介性シグナル伝達の阻害剤
|
|
KR102741437B1
(ko)
*
|
2018-03-22 |
2024-12-10 |
브리스톨-마이어스 스큅 컴퍼니 |
Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 피리딘을 포함하는 헤테로시클릭 화합물
|
|
US12454520B2
(en)
|
2018-07-06 |
2025-10-28 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
CN113271940A
(zh)
|
2018-10-15 |
2021-08-17 |
林伯士拉克许米公司 |
Tyk2抑制剂和其用途
|
|
KR102858043B1
(ko)
*
|
2018-10-30 |
2025-09-10 |
브리스톨-마이어스 스큅 컴퍼니 |
Il-12, il-23 및/또는 ifn-알파의 조정과 관련된 상태의 치료를 위한 아미드-치환된 헤테로시클릭 화합물
|
|
KR102891608B1
(ko)
|
2018-11-30 |
2025-11-28 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Irak 분해제 및 이의 용도
|
|
WO2020112937A1
(en)
|
2018-11-30 |
2020-06-04 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
WO2020154474A1
(en)
|
2019-01-23 |
2020-07-30 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
CN115448910B
(zh)
*
|
2019-01-28 |
2024-04-19 |
江苏豪森药业集团有限公司 |
一种哒嗪类衍生物抑制剂、其制备方法和应用
|
|
KR20220035447A
(ko)
|
2019-07-18 |
2022-03-22 |
브리스톨-마이어스 스큅 컴퍼니 |
IRAK4 억제제로서 유용한 피라졸로[3,4-d]피롤로[1,2-b]피리다지닐 화합물
|
|
WO2021011724A1
(en)
|
2019-07-18 |
2021-01-21 |
Bristol-Myers Squibb Company |
Tricyclic heteroaryl compounds useful as irak4 inhibitors
|
|
US12304916B2
(en)
|
2019-07-23 |
2025-05-20 |
Bristol-Myers Squibb Company |
Thienopyridinyl and thiazolopyridinyl compounds useful as IRAK4 inhibitors
|
|
ES2983263T3
(es)
|
2019-08-06 |
2024-10-22 |
Bristol Myers Squibb Co |
Compuestos heterocíclicos bicíclicos útiles como inhibidores de IRAK4
|
|
MX2022002877A
(es)
|
2019-09-13 |
2022-08-08 |
Nimbus Saturn Inc |
Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
|
|
US12391702B2
(en)
|
2020-02-03 |
2025-08-19 |
Bristol-Myers Squibb Company |
Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as IRAK4 inhibitors
|
|
WO2021158498A1
(en)
|
2020-02-03 |
2021-08-12 |
Bristol-Myers Squibb Company |
Tricyclic heteroaryl compounds useful as irak4 inhibitors
|
|
US20220330549A1
(en)
*
|
2020-03-11 |
2022-10-20 |
Northwest A&F University |
Use of n-benzylbenzamide-based compound as herbicide
|
|
CN115702145A
(zh)
*
|
2020-04-14 |
2023-02-14 |
戈萨默生物服务公司 |
用于治疗炎性疾病的取代的吡啶
|
|
WO2021222153A1
(en)
*
|
2020-04-28 |
2021-11-04 |
Bristol-Myers Squibb Company |
Substituted n-(methyl-d3)pyridazine-3-carboxamide or n-(methyl-d3)-nicotinamide compounds as il-12, il-23 and/or ifnalpha modulators
|
|
KR20230038740A
(ko)
*
|
2020-08-07 |
2023-03-21 |
파마블럭 사이언시스 (난징), 인코포레이티드 |
Cdk9 억제제 및 이의 용도
|
|
CN114181257B
(zh)
*
|
2020-09-14 |
2025-02-14 |
四川科伦博泰生物医药股份有限公司 |
吡啶类化合物，包含其的药物组合物，其制备方法及其用途
|
|
JP2023546996A
(ja)
|
2020-10-23 |
2023-11-08 |
ニンバス クロソー， インコーポレイテッド |
Ｃｔｐｓ１阻害剤およびその使用
|
|
US20240076285A1
(en)
*
|
2020-12-16 |
2024-03-07 |
Shankar Venkatraman |
Compounds and compositions for treating conditions associated with sting activity
|
|
CN116867758A
(zh)
|
2020-12-30 |
2023-10-10 |
凯麦拉医疗公司 |
Irak降解剂和其用途
|
|
CA3206501A1
(en)
|
2021-02-02 |
2022-08-11 |
Shaun Abbott |
Gpr84 antagonists and uses thereof
|
|
EP4288430A1
(en)
|
2021-02-02 |
2023-12-13 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
|
US12252488B2
(en)
|
2021-02-12 |
2025-03-18 |
Nimbus Saturn, Inc. |
HPK1 antagonists and uses thereof
|
|
MX2023009527A
(es)
|
2021-02-15 |
2023-08-24 |
Kymera Therapeutics Inc |
Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
|
|
WO2022175747A1
(en)
|
2021-02-19 |
2022-08-25 |
Sudo Biosciences Limited |
Tyk2 inhibitors and uses thereof
|
|
WO2022175745A1
(en)
*
|
2021-02-19 |
2022-08-25 |
Sudo Biosciences Limited |
Tyk2 inhibitors and uses thereof
|
|
KR20230159421A
(ko)
*
|
2021-02-19 |
2023-11-21 |
수도 바이오사이언시즈 리미티드 |
Tyk2 억제제 및 이의 용도
|
|
BR112023016678A2
(pt)
*
|
2021-02-19 |
2023-11-14 |
Sudo Biosciences Ltd |
Inibidores de tyk2 e usos dos mesmos
|
|
US11926625B2
(en)
|
2021-03-05 |
2024-03-12 |
Nimbus Saturn, Inc. |
HPK1 antagonists and uses thereof
|
|
JP2024513011A
(ja)
|
2021-03-29 |
2024-03-21 |
ニンバス サターン， インコーポレイテッド |
Ｈｐｋ１アンタゴニスト及びその使用
|
|
WO2022217276A1
(en)
|
2021-04-09 |
2022-10-13 |
Nimbus Clio, Inc. |
Cbl-b modulators and uses thereof
|
|
WO2023076161A1
(en)
|
2021-10-25 |
2023-05-04 |
Kymera Therapeutics, Inc. |
Tyk2 degraders and uses thereof
|
|
IL312397A
(en)
|
2021-10-29 |
2024-06-01 |
Kymera Therapeutics Inc |
IRAK4 subunits and their synthesis
|
|
WO2023108536A1
(en)
*
|
2021-12-16 |
2023-06-22 |
Lynk Pharmaceuticals Co. Ltd. |
Tyk2 inhibitors and compositions and methods thereof
|
|
JP2025503448A
(ja)
|
2021-12-16 |
2025-02-04 |
リンク ファーマシューティカルズ シーオー．エルティーディー． |
Ｔｙｋ２阻害剤および組成物ならびにその方法
|
|
US12091411B2
(en)
|
2022-01-31 |
2024-09-17 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
CN116693449A
(zh)
|
2022-03-04 |
2023-09-05 |
上海致根医药科技有限公司 |
用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用
|
|
CN119585250A
(zh)
*
|
2022-04-19 |
2025-03-07 |
蓝图药品公司 |
Kit抑制剂
|
|
WO2023227946A1
(en)
*
|
2022-05-27 |
2023-11-30 |
Sudo Biosciences Limited |
Tyk2 inhibitors and uses thereof
|
|
IL318576A
(en)
|
2022-08-02 |
2025-03-01 |
Liminal Biosciences Ltd |
Pyridoxine-substituted GPR84 antagonists and their uses
|
|
AU2023317740A1
(en)
|
2022-08-02 |
2025-03-13 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
|
KR20250057801A
(ko)
|
2022-08-02 |
2025-04-29 |
리미널 바이오사이언시스 리미티드 |
아릴-트라이아졸릴 및 관련 gpr84 길항제 및 이의 용도
|
|
WO2024249855A1
(en)
*
|
2023-06-02 |
2024-12-05 |
Idrx, Inc. |
Combination therapy comprising kit inhibitors for use in the treatment of cancer
|
|
WO2025062372A1
(en)
|
2023-09-21 |
2025-03-27 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors for use in the treatment of inflammatory bowel disease
|